Pasithea Therapeutics Corp. (KTTA) announced promising initial results from its Phase 1 clinical trial of PAS-004, a novel macrocyclic MEK inhibitor designed for the treatment of neurofibromatosis type 1 and various cancers. This positive news has driven the stock up by 76%.
The trial, conducted across four U.S. locations, demonstrated favorable outcomes in terms of safety, tolerability, pharmacokinetics, and early efficacy indicators.
Key findings include the absence of treatment-related side effects or dose-limiting toxicities, a lengthy half-life of approximately 70 hours allowing for once-daily or less frequent oral dosing, consistent target inhibition without peak plasma toxicities, and a patient with stage 3 colon cancer achieving prolonged stable disease.
The company expresses optimism about PAS-004's unique profile as an MEK inhibitor.
Presently, KTTA's stock is trading at $6.77 on the Nasdaq, marking a 76.07% increase.
